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This, in combination with available package insert data,
supports a wider range of options for preparation. In
December 2011 we implemented a simpler technique for
administration of melphalan by preparing all doses in a total
volume of 250 mL NS. This method yields concentrations
between 0.45 to 2 mg/mL for patients of a BSA from 0.81 to
3.56 m2 for 140 mg/m2 doses and 0.57 to 2.5 m2 for 200 mg/
m2 doses. In a review of the ﬁrst 30 autologous HCT patients
who received melphalan 200 mg/m2 via this method, me-
dian engraftment was on days 12 and 16 for neutrophils and
platelets, respectfully, which is the same as our historical
data for this transplant regimen. To date this method has
been used for over 350 transplant patients. This practice
change simpliﬁed both pharmacy and nursing procedures
such that all doses are dispensed in a single bag with a total
volume of 250 mL and infused via one infusion pump at a
standard rate of 500 mL/hour. This simpliﬁed compounding
and administration of doses decreases time spent by both
pharmacy and nursing for treatments using melphalan. The
use of a single bag and one standard infusion rate also re-
duces the likelihood of administration errors by eliminating
the need to calculate infusion rates and coordinate the use of
multiple pumps.456
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Background: Busulfan is an alkylating agent commonly used
for myeloablation in hematopoietic stem cell transplantation
(SCT). Narrow therapeutic index and 2-3 fold interpatient PK
variability underscores the need to further explore predictors
of busulfan clearance. This analysis aimed to predict the
percentage of patients who were within the targeted AUC
range of 4800 mM*minwith dosing strategies based on actual
body weight (ABW) or adjusted body weight (AdBW, and to
determine patient characteristics that may impact busulfan
clearance.
Methods: This retrospective analysis assessed allogeneic SCT
patients who received a test dose of 0.8 mg/kg IV busulfan,
dosed by AdBW, prior to conditioning therapy containing
therapeutically dosed busulfan. All patients were treated
between June 2004 and July 2013 at the University of North
Carolina at Chapel Hill. Noncompartmental PK parameters
were calculated from this test dose using Phoenix
WinNonlinPharsight software. Measured PK data were
obtained from test the test dose and used to extrapolate an
AUC for ABWand AdBW. Acceptable AUCs werewithin 15% of
the targeted of 4800 mM*min.
A linear model with log of busulfan test dose clearance as
an outcome and patient characteristics that included disease
state, bone marrow donor type, gender, race, ethnicity, body
surface area (BSA), anticonvulsant prophylaxis used (leve-
tiracetam or phenytoin), total bilirubin and serum creatinine
was ﬁt.
Results: The study reviewed a total of 102 patients with a
mean age of 40.3 (range 18 to 63). The analysis included 63males, 87 Caucasians, and 5 African Americans. Seizure
prophylaxis with levetiracetamwas given to 41 patients, and
51 patients received phenytoin. Based extrapolated PK data,
42% of patients dosed by ABW were within targeted AUC
range, versus 47% of patients dosed by AdBW.
After adjusting for patient characteristics, a unit increase
in BSA was associated with 0.68 (p ¼ < 0.001) increase in
busulfan log(clearance). Although not statistically signiﬁcant,
African American race was associated with a trend towards
decreased clearance (p ¼ 0.064). No correlation was seen for
age (p ¼ 0.226), gender (p ¼ 0.417337), or for any other
variable that was assessed.
Discussion: Weight-based busulfan dosing using AdBW or
ABW each results in <50% of patients being achieving a goal
AUC of 4800 mM*min. Interpatient variability of IV busulfan
may be partially explained by BSA, yet differences in race,
gender, and age did not correlate busulfan clearance. These
data suggest that other dosing strategies, such as PK-guided
dosing, may help to minimize over/under dosing and to
overcome interpatient variability.457
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Background: Allogeneic hematopoietic cell transplant (HCT)
is increasingly used to treat patients with malignancies. The
use of pre-HCT immunosuppressive conditioning chemo-
therapy and post-HCT immunosuppression predispose these
patients to infections. A departmental vaccination guideline
was implemented in Singapore General Hospital (SGH) in
year 2004. As a clinical improvement initiative to facilitate
easy reference and prompt prescribing, the guideline was
updated and modiﬁed into a vaccination chart detailing the
vaccines needed at various time-points in October 2012. This
chart was ﬁled in the patients’ progress notes to ensure ac-
curate tracking of patients’ vaccination status. The aim of this
study was to review the usefulness of this chart in facilitating
prompt prescribing.
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went allogeneic HCT in SGH between January 2005 and
December 2010, with at least one year follow-up, was carried
out for the pre-implementation phase. Patients who under-
went allogeneic and autologous HCT between May 2012 and
February 2013, with at least six months follow-up were
reviewed for the post-implementation phase. Primary
endpoint was the overall vaccination rate. Secondary end-
points included the time to ﬁrst vaccination and infection
rate.
Results: Eighty-one evaluable patients were included in the
pre-implementation phase, of whom, 41 did not receive any
vaccination. In the post-implementation phase, among the
39 evaluable patients, only 9 did not receive any vaccination.
Among those vaccinated, median time to ﬁrst vaccination
was 20 (range, 4-72) months post-HCT in the pre-imple-
mentation phase versus 6 (range, 4-13) months post-HCT in
the post-implementation phase. Overall vaccination rate at
various time-points was 3.4% and 59.3% for the pre- and
post-implementation group, respectively (p<0.05). Inﬂuenza
infection occurred in 18 (22.2%) patients pre-implementa-
tion as compared to 3 (7.7%) post-implementation. Of note,
these infections occurred in patients who did not receive
inﬂuenza vaccine.
Conclusions: The vaccination chart detailing the required
vaccines at various time-points post-HCT proved to be a
useful aid in facilitating timely prescribing and accurate
tracking of vaccination status. Timely administration of
required vaccines may result in reduced infectious compli-
cations. Importance of more effective strategies to further
improve vaccination rates in this high risk population is
underscored.458
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Background: Plerixafor (Mozobil) has been approved for use
in multiple myeloma (MM) and non-Hodgkin lymphoma
(NHL) patients (pts) in combination with G-CSF to mobilize
hematopoetic stem cells (CD34) in collection for autologous
transplant (tx). Many different mobilization approaches exist
in this ﬁeld, and we evaluate the role of Plerixafor in MM and
amyloidosis (AL) pts.
Methods: To evaluate plerixafor mobilization in the trans-
plant setting, all MM and AL patients whoweremobilized for
autologous stem cell transplant (autoSCT) between 2010 and
2012 were included. Sufﬁcient CD34+ cell collection was
deﬁned both using a minimal cutpoint of 2x106 as well as an
optimal goal of 5x106 CD34 cells. Signiﬁcant inﬂuences on
the ability to achieve these collection goals on day 1 and
across all collections were evaluated using univariate logistic
regression models in addition to graphical analyses and two
sample tests. In addition to clinical characteristics, weassessed the impact of plerixafor mobilization use and also
lenalidomide and thalidomide use on these outcomes.
Results: Overall, 196 pts (10 AL, 182 MM, 4 MM/AL) were
mobilized for autoSCTs from 2010-2012. Most pts were male
(60%), most were Caucasian (88%), and the median age at
transplant was 59 years (range: 18 to 73). About half of pts
(52%) received lenalidomide (lena), and only 5% received
thalidomide prior to mobilization; the median number of
lena cycles was 4 (range: 1 to 11). Comorbidity indices were
similar to those who did vs. did not receive plerixafor
(p¼0.8). On day 1 collections, 154 pts achieved a yield of
>2x106 and 87 pts>5x106 CD34+ cells. Across all collections,
all but 2 pts had a total yield of at least 2 million CD34 cells,
and 152 had at least 5x106 CD34 cells. Several factors
appeared to inﬂuence a pts ability to achieve a yield of
>5x106 CD34+ cells: age (OR¼0.94, p¼0.014), day 1 yield of
>2x106 CD34+ cells (OR¼14.5, p<0.0001), and the total
number of collections (OR¼0.32, p<0.0001). Days to ANC
recovery after transplant was also borderline associated with
a total yield of at least 5x106 CD34+ cells (OR¼0.82,
p¼0.075). While lena use was not signiﬁcantly associated
with total yield of 5 million CD34+ cells, pts who had prior
lenawere less likely to achieve a yield of at least 2x106 CD34+
cells on day 1 collection vs. those who did not (OR¼0.48,
p¼0.045). Prior radiation therapy was not signiﬁcantly
associated with any of the collection goal metrics. Plerixafor
use was not signiﬁcantly associated with the ability to ach-
ieve a yield of 5x106 CD34+ cells on day 1 or in total; how-
ever, plerixafor use was signiﬁcantly associated with not
achieving a day 1 collection of at least 2x106 CD34+ cells
(OR¼0.24, p¼0.0007); however, this is likely due more to the
decision algorithms used to determine administration of
plerixafor for mobilization prior to autoSCT than a statement
on the effectiveness of plerixafor as a mobilizing agent.459
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Background: Melphalan at a dose of 200 mg/m2 IV (MEL
200) is considered the standard preparative regimen for
autologous hematopoietic stem cell transplantation (auto-
HCT) for multiple myeloma. However, reduced doses of
melphalan such as140 mg/m2 IV (MEL 140) are often used in
older patients or patients with renal dysfunction.
Methods: The purpose of this retrospective analysis was to
determine if there was a difference in toxicity, treatment-
related mortality (TRM), response rate, progression- free
survival (PFS) or overall survival (OS) in patients that
received 140 mg/m2 of melphalan (MEL 140) compared to
those receiving MEL 200 for auto-HCT. From June 1, 1996
through December 31, 2012, 63 patients received MEL 140.
We compared their outcomes with 252 patients that
received MEL 200.
